AACR II: Race-Based Survival Differences in Patients With CML Living in Texas
Posted: Friday, June 26, 2020
Hispanic patients with chronic myeloid leukemia (CML) who are living along the United States/Mexico border in El Paso, Texas, seem to have a worse overall survival compared with Hispanic patients with CML diagnosed in other parts of Texas, according to a retrospective analysis presented at the American Association for Cancer Research Virtual Annual Meeting II (Abstract 4343/7). In addition, these study findings from the Texas Cancer Registry for hematologic malignancies showed a surprisingly better overall survival in Hispanic patients with CML, acute myeloid leukemia (AML), and myelodysplastic syndromes compared with non-Hispanic white patients.
“Hispanic individuals living at the border tend to be poorer, are more likely to lack health insurance, and many could be undocumented,” explained lead study author Alfonso Bencomo-Alvarez, PhD, of Texas Tech University Health Sciences Center, El Paso, in an AACR press release.
From 1995 to 2016, data on 69,941 Hispanic and non-Hispanic white patients with hematologic malignancies were collected from the Texas Cancer Registry. To understand how living near the United States/Mexico border might impact survival, the investigators focused on 1,160 Hispanic patients residing in El Paso, Texas, and 9,662 Hispanic patients living in other parts of the state.
The investigators reported that Hispanic patients were younger at the time of diagnosis compared with non-Hispanic white patients. According to the investigators, this younger age at diagnosis may explain the significantly better overall survival in Hispanic patients with CML, AML, and myelodysplastic syndromes than in non-Hispanic white patients observed in unadjusted analyses. Overall survival was significantly reduced in Hispanic patients with CML living in El Paso compared with Hispanic patients living elsewhere in Texas (P = .016). In addition, Hispanic patients with CML living near the United States/Mexico border had significantly lower 10-year survival rates than patients living in other areas of the state (43% vs. 57%).
Disclosure: The study authors did not disclose any conflicts of interest.